Abstract
The δ-opioid antagonist naltrindole has been shown to inhibit graft rejection in vivo and suppress allogeneic mixed lymphocyte reaction (MLR) in vitro, similarly to cyclosporin A. We investigated whether this action is mediated by δ-opioid receptors using both genetic and pharmacological tools. Naltrindole and two related compounds, 7-benzylidene-7-dehydronaltrexone and naltriben, inhibited MLR performed with lymphocytes from wild-type and δ-opioid receptor knockout mice, with comparable potency. Furthermore, these compounds suppressed the proliferation of spleen cells from triple δ/μ/κ-opioid receptor-deficient animals as well. Finally, the highly δ-selective, but structurally distinct, antagonistN,N-dimethyl-Dmt-Tic-OH and the general opioid antagonist naltrexone were inactive in the MLR assay. In conclusion, we demonstrate for the first time that the immunosuppressive activity of naltrindole and close derivatives is not mediated by any of the three cloned opioid receptors. Therefore, the postulated inhibitory activity of naltrindole in the graft rejection process is mediated by a target, which remains to be discovered.
Footnotes
-
This work was funded by the Center National de la Recherché Scientifique, Association pour la Recherché sur le Cancer, The Foundation UPSA pour la Douleur.
- Abbreviations:
- MLR
- mixed lymphocyte reaction
- BNTX
- 7-benzylidene-7-dehydronaltrexone
- DOR
- δ-opioid receptor
- MOR
- μ-opioid receptor
- KOR
- κ-opioid receptor
- IL-2
- interleukin-2
- Received March 5, 2001.
- Accepted May 31, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
